Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course.
Main Authors: | , , , , , , , |
---|---|
Format: | Artículo biblioteca |
Language: | eng eng |
Published: |
Lippincott, Williams & Wilkins
2012
|
Subjects: | PREGABALINA, SUEÑO, DOLOR, CALIDAD DE VIDA, SALUD, |
Online Access: | https://repositorio.uca.edu.ar/handle/123456789/1624 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:ucacris:123456789-1624 |
---|---|
record_format |
koha |
spelling |
oai:ucacris:123456789-16242020-08-06T19:41:42Z Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course Pérez Lloret, Santiago Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course. 2019-05-02T14:01:10Z 2019-05-02T14:01:10Z 2012 Artículo Pérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624 0362-5664 1537-162X (online) https://repositorio.uca.edu.ar/handle/123456789/1624 10.1097/WNF.0b013e31823df2dc eng eng Acceso Abierto https://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Lippincott, Williams & Wilkins Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1) |
institution |
UCA |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-uca |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Sistema de bibliotecas de la UCA |
language |
eng eng |
topic |
PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD |
spellingShingle |
PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD Pérez Lloret, Santiago Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
description |
Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course. |
format |
Artículo |
topic_facet |
PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD |
author |
Pérez Lloret, Santiago Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro |
author_facet |
Pérez Lloret, Santiago Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro |
author_sort |
Pérez Lloret, Santiago |
title |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_short |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_full |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_fullStr |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_full_unstemmed |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_sort |
pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
publisher |
Lippincott, Williams & Wilkins |
publishDate |
2012 |
url |
https://repositorio.uca.edu.ar/handle/123456789/1624 |
work_keys_str_mv |
AT perezlloretsantiago pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse AT mezarojasgloria pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse AT menonimariacelia pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse AT ruizgabriela pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse AT velasquezcarolina pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse AT rodriguezhernan pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse AT reyveronica pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse AT cardinalidanielpedro pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse |
_version_ |
1756275062540861440 |